Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Mar 09 2022 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference Feb 07 2022 Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 Dec 23 2021 Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference Nov 10 2021 Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 05 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes Oct 29 2021 Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update Sep 08 2021 Cyclacel Pharmaceuticals Presenting at Three Conferences in September Aug 11 2021 Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Aug 03 2021 Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update Jul 13 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas Jul 07 2021 Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference May 12 2021 Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results May 05 2021 Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update Mar 16 2021 Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Mar 15 2021 Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference Mar 12 2021 Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock Mar 11 2021 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 25 2021 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Feb 19 2021 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results Feb 10 2021 Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Mar 09 2022 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference Feb 07 2022 Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 Dec 23 2021 Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference Nov 10 2021 Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 05 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes Oct 29 2021 Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update Sep 08 2021 Cyclacel Pharmaceuticals Presenting at Three Conferences in September Aug 11 2021 Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Aug 03 2021 Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update Jul 13 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas Jul 07 2021 Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference May 12 2021 Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results May 05 2021 Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update Mar 16 2021 Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Mar 15 2021 Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference Mar 12 2021 Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock Mar 11 2021 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 25 2021 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Feb 19 2021 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results Feb 10 2021 Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
Nov 10 2021 Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 05 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Oct 29 2021 Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
Aug 11 2021 Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 03 2021 Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
Jul 13 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
Jul 07 2021 Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
May 05 2021 Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update
Mar 16 2021 Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Mar 12 2021 Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock
Feb 10 2021 Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference
